We devise an approach for targeted molecular design, a problem of interest in computational drug discovery: given a target protein site, we wish to generate a chemical with both high binding affinity to the target and satisfactory pharmacological properties. This problem is made difficult by the enormity and discreteness of the space of potential therapeutics, as well as the graph-structured nature of biomolecular surface sites. Using a dataset of protein-ligand complexes, we surmount these issues by extracting a signature of the target site with a graph convolutional network and by encoding the discrete chemical into a continuous latent vector space. The latter embedding permits gradient-based optimization in molecular space, which we perform using learned differentiable models of binding affinity and other pharmacological properties. We show that our approach is able to efficiently optimize these multiple objectives and discover new molecules with potentially useful binding properties, validated via docking methods.
Separately, methods of predicting affinity from structural information have also been recently developed @cite_58 @cite_21 . Such networks take a PLC as input, and use the structural information from the complex to score the affinity of the bound pair. The main difference between our method and these approaches is that our affinity prediction network does not receive structural information on the interaction; i.e. the protein site and putative binding chemical are received independently, as embedded vectors. This makes the estimation problem more difficult, since detailed atomic interaction information is not available to the predictor, but more general, since it can be applied to any protein site-chemical pair. This allows us to avoid a docking step (i.e. to generate a PLC) during our optimization.
@cite_58 @cite_21
2604306554 2583907533
Empirical scoring functions based on either molecular force fields or cheminformatics descriptors are widely used, in conjunction with molecular docking, during the early stages of drug discovery to predict potency and binding affinity of a drug-like molecule to a given target. These models require expert-level knowledge of physical chemistry and biology to be encoded as hand-tuned parameters or features rather than allowing the underlying model to select features in a data-driven procedure. Here, we develop a general 3-dimensional spatial convolution operation for learning atomic-level chemical interactions directly from atomic coordinates and demonstrate its application to structure-based bioactivity prediction. The atomic convolutional neural network is trained to predict the experimentally determined binding affinity of a protein-ligand complex by direct calculation of the energy associated with the complex, protein, and ligand given the crystal structure of the binding pose. Non-covalent interactions present in the complex that are absent in the protein-ligand sub-structures are identified and the model learns the interaction strength associated with these features. We test our model by predicting the binding free energy of a subset of protein-ligand complexes found in the PDBBind dataset and compare with state-of-the-art cheminformatics and machine learning-based approaches. We find that all methods achieve experimental accuracy and that atomic convolutional networks either outperform or perform competitively with the cheminformatics based methods. Unlike all previous protein-ligand prediction systems, atomic convolutional networks are end-to-end and fully-differentiable. They represent a new data-driven, physics-based deep learning model paradigm that offers a strong foundation for future improvements in structure-based bioactivity prediction. Computational approaches to drug discovery can reduce the time and cost associated with experimental assays and enable the screening of novel chemotypes. Structure-based drug design methods rely on scoring functions to rank and predict binding affinities and poses. The ever-expanding amount of protein–ligand binding and structural data enables the use of deep machine learning techniques for protein–ligand scoring. We describe convolutional neural network (CNN) scoring functions that take as input a comprehensive three-dimensional (3D) representation of a protein–ligand interaction. A CNN scoring function automatically learns the key features of protein–ligand interactions that correlate with binding. We train and optimize our CNN scoring functions to discriminate between correct and incorrect binding poses and known binders and nonbinders. We find that our CNN scoring function outperforms the AutoDock Vina scoring function when ranking poses both for pose prediction and virtual screening.